NEW YORK (
) hit a new 52-week high Friday as it is currently trading at $30.90, above its previous 52-week high of $30.86 with 523,039 shares traded as of 10:57 a.m. ET. Average volume has been 850,600 shares over the past 30 days.
BioMarin has a market cap of $3.3 billion and is part of the
industry. Shares are up 8.8% year to date as of the close of trading on Thursday.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates. The company has a P/E ratio of 17.6, below the average drugs industry P/E ratio of 18.2 and below the S&P 500 P/E ratio of 17.7.
- Practice your BMRN trading strategies and win cash in our stock game.
TheStreet Ratings rates BioMarin as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share. You can view the full
52-week high stocks
or get investment ideas from our